CA2978073A1 - Use of ferric citrate in the treatment of iron-deficiency anemia - Google Patents

Use of ferric citrate in the treatment of iron-deficiency anemia Download PDF

Info

Publication number
CA2978073A1
CA2978073A1 CA2978073A CA2978073A CA2978073A1 CA 2978073 A1 CA2978073 A1 CA 2978073A1 CA 2978073 A CA2978073 A CA 2978073A CA 2978073 A CA2978073 A CA 2978073A CA 2978073 A1 CA2978073 A1 CA 2978073A1
Authority
CA
Canada
Prior art keywords
approximately
iron
ferric citrate
months
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978073A
Other languages
English (en)
French (fr)
Inventor
Enrique Poradosu
Shay David Shemesh
Ron BENTSUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of CA2978073A1 publication Critical patent/CA2978073A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2978073A 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia Abandoned CA2978073A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127963P 2015-03-04 2015-03-04
US62/127,963 2015-03-04
PCT/US2016/020575 WO2016141124A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Publications (1)

Publication Number Publication Date
CA2978073A1 true CA2978073A1 (en) 2016-09-09

Family

ID=56848619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978073A Abandoned CA2978073A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Country Status (15)

Country Link
US (2) US20180071243A1 (enExample)
EP (1) EP3265077A4 (enExample)
JP (2) JP2018507260A (enExample)
KR (1) KR20170123664A (enExample)
CN (1) CN107530310A (enExample)
AU (1) AU2016226250B2 (enExample)
BR (1) BR112017018963A2 (enExample)
CA (1) CA2978073A1 (enExample)
EA (1) EA201791960A1 (enExample)
HK (2) HK1248589A1 (enExample)
IL (1) IL254125A0 (enExample)
MX (1) MX2017011169A (enExample)
SG (1) SG11201707120PA (enExample)
TW (2) TW202302083A (enExample)
WO (1) WO2016141124A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US20210085711A1 (en) * 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
FR3075601A1 (fr) * 2017-12-21 2019-06-28 Clarisse Le Court Complements alimentaires et leur utilisation sur les menstruations
US12467933B2 (en) 2019-06-07 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Body fluid iron level panel analyzer
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2023047424A1 (en) * 2022-04-29 2023-03-30 West Bengal Chemical Industries Limited Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
CA2552889A1 (en) * 2004-01-14 2005-07-28 Sachiko Suzuki Iron supplement and utilization of the same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2012097155A1 (en) * 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
HK1246649A1 (zh) 2018-09-14
TW202302083A (zh) 2023-01-16
JP2018507260A (ja) 2018-03-15
KR20170123664A (ko) 2017-11-08
WO2016141124A1 (en) 2016-09-09
CN107530310A (zh) 2018-01-02
BR112017018963A2 (pt) 2018-05-15
EP3265077A1 (en) 2018-01-10
HK1248589A1 (zh) 2018-10-19
EP3265077A4 (en) 2018-10-24
TW201639558A (zh) 2016-11-16
TWI812580B (zh) 2023-08-21
EA201791960A1 (ru) 2018-01-31
US20240075006A1 (en) 2024-03-07
SG11201707120PA (en) 2017-09-28
MX2017011169A (es) 2017-11-09
JP2021091686A (ja) 2021-06-17
AU2016226250A1 (en) 2017-09-28
IL254125A0 (en) 2017-10-31
US20180071243A1 (en) 2018-03-15
AU2016226250B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
AU2016226250B2 (en) Use of ferric citrate in the treatment of iron-deficiency anemia
AU2018203205B2 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
JP6828100B2 (ja) 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2025122089A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
JPWO2019059172A1 (ja) 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
CN118382439A (zh) 用于治疗mds相关贫血和其他病症的化合物
HK1210013B (en) Use of ferric citrate in the treatment of chronic kidney disease patients

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220525